Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to $11.4 million.

  • Ani Pharmaceuticals' Other Non-Current Liabilities fell 4359.85% to $11.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.4 million, marking a year-over-year decrease of 4359.85%. This contributed to the annual value of $19.8 million for FY2024, which is 1739.58% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Other Non-Current Liabilities of $11.4 million as of Q3 2025, which was down 4359.85% from $18.1 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $35.1 million in Q4 2022 and a low of $8.1 million during Q3 2021
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $17.4 million (2025), whereas its average is $18.9 million.
  • In the last 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities soared by 31195.17% in 2022 and then tumbled by 6841.54% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $31.0 million in 2021, then grew by 13.09% to $35.1 million in 2022, then crashed by 31.54% to $24.0 million in 2023, then fell by 17.4% to $19.8 million in 2024, then tumbled by 42.6% to $11.4 million in 2025.
  • Its last three reported values are $11.4 million in Q3 2025, $18.1 million for Q2 2025, and $17.4 million during Q1 2025.